210 related articles for article (PubMed ID: 22059351)
1. CD40 ligand, Bcl-2 and apoptosis in B-chronic lymphocytic leukemia.
Hussein OA; Omran AA; Elnaggar AM; Fathy A
Egypt J Immunol; 2009; 16(2):27-36. PubMed ID: 22059351
[TBL] [Abstract][Full Text] [Related]
2. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells.
Coscia M; Pantaleoni F; Riganti C; Vitale C; Rigoni M; Peola S; Castella B; Foglietta M; Griggio V; Drandi D; Ladetto M; Bosia A; Boccadoro M; Massaia M
Leukemia; 2011 May; 25(5):828-37. PubMed ID: 21372840
[TBL] [Abstract][Full Text] [Related]
3. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
[TBL] [Abstract][Full Text] [Related]
4. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1.
Pedersen IM; Kitada S; Leoni LM; Zapata JM; Karras JG; Tsukada N; Kipps TJ; Choi YS; Bennett F; Reed JC
Blood; 2002 Sep; 100(5):1795-801. PubMed ID: 12176902
[TBL] [Abstract][Full Text] [Related]
5. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.
Chu P; Deforce D; Pedersen IM; Kim Y; Kitada S; Reed JC; Kipps TJ
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3854-9. PubMed ID: 11891278
[TBL] [Abstract][Full Text] [Related]
6. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.
Furman RR; Asgary Z; Mascarenhas JO; Liou HC; Schattner EJ
J Immunol; 2000 Feb; 164(4):2200-6. PubMed ID: 10657675
[TBL] [Abstract][Full Text] [Related]
7. Abnormal intracellular level of Bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients.
Scamardella F; Maconi M; Albertazzi L; Gamberi B; Gugliotta L; Brini M
Lab Hematol; 2006; 12(4):187-92. PubMed ID: 17118768
[TBL] [Abstract][Full Text] [Related]
8. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia.
Kitada S; Zapata JM; Andreeff M; Reed JC
Br J Haematol; 1999 Sep; 106(4):995-1004. PubMed ID: 10520003
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic analysis of receptor-ligand pairs on B-cells in B-chronic lymphocytic leukemia.
Gagro A; Dasić G; Sabioncello A; Rabatić S; Reckzeh B; Havemann K; Kardum I; Jacksić B; Vitale B
Leuk Lymphoma; 1997 Apr; 25(3-4):301-11. PubMed ID: 9168440
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand.
Buske C; Gogowski G; Schreiber K; Rave-Fränk M; Hiddemann W; Wörmann B
Exp Hematol; 1997 Apr; 25(4):329-37. PubMed ID: 9131008
[TBL] [Abstract][Full Text] [Related]
11. CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia.
Willimott S; Baou M; Naresh K; Wagner SD
Br J Haematol; 2007 Sep; 138(6):721-32. PubMed ID: 17760804
[TBL] [Abstract][Full Text] [Related]
12. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia.
Jak M; Mous R; Remmerswaal EB; Spijker R; Jaspers A; Yagüe A; Eldering E; Van Lier RA; Van Oers MH
Leuk Lymphoma; 2009 May; 50(5):788-801. PubMed ID: 19452318
[TBL] [Abstract][Full Text] [Related]
13. CD40 ligand in CLL pathogenesis and therapy.
Schattner EJ
Leuk Lymphoma; 2000 May; 37(5-6):461-72. PubMed ID: 11042507
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 regulatory pathway is functional in chronic lymphocytic leukemia.
Goolsby C; Paniagua M; Tallman M; Gartenhaus RB
Cytometry B Clin Cytom; 2005 Jan; 63(1):36-46. PubMed ID: 15624202
[TBL] [Abstract][Full Text] [Related]
15. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.
Younes A; Snell V; Consoli U; Clodi K; Zhao S; Palmer JL; Thomas EK; Armitage RJ; Andreeff M
Br J Haematol; 1998 Jan; 100(1):135-41. PubMed ID: 9450802
[TBL] [Abstract][Full Text] [Related]
16. Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment: sCD40L-caspase 3 chimeric protein for treating B-cell malignancies.
Kedar R; Sabag O; Licthenstein M; Lorberboum-Galski H
Cancer; 2012 Dec; 118(24):6089-104. PubMed ID: 22692727
[TBL] [Abstract][Full Text] [Related]
17. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.
Romano C; De Fanis U; Sellitto A; Dalla Mora L; Chiurazzi F; Giunta R; Rotoli B; Lucivero G
Leuk Lymphoma; 2003 Nov; 44(11):1963-71. PubMed ID: 14738151
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.
Hayden RE; Pratt G; Roberts C; Drayson MT; Bunce CM
Leuk Lymphoma; 2012 Apr; 53(4):537-49. PubMed ID: 21812539
[TBL] [Abstract][Full Text] [Related]
19. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies.
Wang D; Freeman GJ; Levine H; Ritz J; Robertson MJ
Br J Haematol; 1997 May; 97(2):409-17. PubMed ID: 9163608
[TBL] [Abstract][Full Text] [Related]
20. FOXP1 and BCL2 show similar immunoenzymatic pattern in bone marrow trephines of chronic lymphocytic leukemia patients.
Korać P; Vintar MG; Ajduković R; Kardum Paro MM; Jaksić B; Dominis M
Appl Immunohistochem Mol Morphol; 2009 Dec; 17(6):500-4. PubMed ID: 19417623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
